Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular ...

For the second time in 16 months, Unity Biotechnology is restructuring its operations. The developer of drugs to treat diseases of aging is cutting its headcount in half to ensure its cash reserves ...

A little more than a year ago, Unity Biotechnology’s future was uncertain after half the workforce was laid off amid a corporate shift toward ophthalmology. But the recalibration appears to be paying ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after ...